Arbutus Biopharma financials
$4.69−3.50%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.1M | $6.2M | $18.1M | $39.0M | $11.0M | $6.9M | $6.0M | $5.9M | $10.7M | $1.5M |
| Gross profit | $14.1M | $6.2M | $18.1M | $39.0M | $11.0M | $6.9M | $6.0M | $5.9M | $10.7M | $1.5M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$38.2M | -$76.3M | -$78.1M | -$65.5M | -$73.5M | -$57.8M | -$143.9M | -$89.8M | -$110.9M | -$491.6M |
| Net income | -$33.5M | -$69.9M | -$72.8M | -$69.5M | -$88.4M | -$75.9M | -$164.9M | -$67.2M | -$85.3M | -$384.2M |
| Net margin | −237.9% | −1133.0% | −401.6% | −178.0% | −804.4% | −1097.3% | −2742.8% | −1129.5% | −797.4% | −25765.5% |
| Diluted EPS | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | $-2.89 | $-1.21 | $-1.56 | $-7.24 |
| EBITDA | -$24.9M | -$71.2M | -$76.7M | -$64.0M | -$69.9M | -$55.3M | -$75.6M | -$68.0M | -$68.1M | -$99.2M |
| Operating cash flow | -$39.6M | -$64.8M | -$85.9M | -$35.4M | -$67.5M | -$51.4M | -$71.0M | -$60.6M | -$50.0M | -$59.5M |
| Free cash flow | -$39.6M | -$65.0M | -$86.9M | -$35.9M | -$68.3M | -$51.7M | -$71.6M | -$61.7M | -$57.3M | -$63.4M |
| Diluted shares | 191.6M | 185.6M | 166.0M | 150.9M | 106.2M | 75.8M | 57.1M | 55.3M | 54.7M | 53.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $18.0M | $36.3M | $26.3M | $30.8M | $109.3M | $52.3M |
| Short-term investments | $73.5M | $86.3M | $99.7M | $116.1M | $46.0M | $71.0M |
| Total debt | $3.4M | $4.8M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $94.6M | $131.7M | $144.4M | $195.4M | $204.5M | $137.1M |
| Total liabilities | $18.0M | $34.3M | $38.4M | $58.6M | $35.0M | $35.1M |
| Shareholders' equity | $76.6M | $97.4M | $106.0M | $136.9M | $169.4M | $102.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology